Lupin Manufacturing Solutions (LMS), the CRDMO arm of Lupin Ltd, is doubling down on its advanced manufacturing capabilities with a strategic expansion of its Dabhasa facility.
The move is part of strategy aimed at capturing growing global demand for complex, next-generation therapeutics. This will also significant step in LMS’s evolution from a traditional API manufacturer to a high-value partner in the global contract development and manufacturing (CRDMO) space.
Building for the Future of Drug Development
The expansion includes a new manufacturing block, complemented by two additional specialised units dedicated to peptide production. This enhanced infrastructure is designed to support advanced drug development programmes, flexible, scalable manufacturing and complex therapeutic modalities including peptides and ADCs.
The facility upgrade will also bolster LMS’s ability to manufacture high-quality peptide building blocks, including protected amino acids, critical components in modern drug discovery.
Riding the Wave of Complex Modalities
The global pharmaceutical landscape is undergoing a structural shift, with innovation increasingly centered around complex molecules such as peptides and antibody-drug conjugates (ADCs). These therapies demand specialised capabilities, stringent quality standards and deep technical expertise.
LMS’s expanded Dabhasa site positions it to meet these evolving requirements while strengthening its role in the global peptide ecosystem.
Lupin Manufacturing Solutions CEO Abdelaziz Toumi emphasised the strategic importance of the expansion.
“As pharmaceutical innovation increasingly shifts toward complex modalities, building deep capabilities and execution excellence has become critical. This expansion underscores our commitment to building advanced, scalable capabilities that support complex development programs and reinforce our role in the global peptide ecosystem, enabling meaningful partnerships with innovators worldwide,” he said.
From APIs To Integrated CRDMO Partner
LMS has been steadily transitioning toward a more integrated CRDMO model, offering end-to-end solutions across drug substances, complex chemistry, Drug product development and advanced modalities such as peptides and ADCs.
This expansion further strengthens its positioning as a global partner for pharmaceutical innovators seeking reliable, high-quality manufacturing support.